+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.

Age: 18Years +All GendersPhase 3
113 locations
E

Actively Recruiting

Researchers are studying outcomes after total shoulder replacement surgery using the PRIMA humeral stem implant. This includes patients receiving either an anatomic or reverse shoulder replacement. The study aims to assess clinical, radiographic, and patient-reported results up to 24 months after surgery, focusing on short-term implant performance, survivorship, and complications. Participants have undergone shoulder arthroplasty with the PRIMA humeral stem in either anatomic or reverse configuration according to standard procedures. The study collects data on these surgeries and follows patients for up to 24 months to monitor changes in shoulder function, implant stability, and adverse events. During the study, participants will have assessments including the Constant Murley Score, American Shoulder and Elbow Surgeons score, range of motion measurements, and radiographic evaluation of the implant. Researchers will also track implant survival rates and record any complications or device-related adverse effects. Follow-up visits occur over two years to collect this information and evaluate overall outcomes.

Age: 18Years +All Genders
1 location